The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Weekend Reading: This Week in the Twitterverse

Social media, publication quality, Canadian VC policy and exhaustion (mine and patents’) make for a light dose of interesting reading this weekend:

  • Friday Science Review: stagnant technologies in Africa, congenital blindness in children and chronic pain in the crosshairs…
  • Social Media Reshaping Healthcare: Some cool data on the use of Twitter as a Public Health Surveillance Tool
    • Also… Deloitte’s report on social networks for lifesciences: Valuable communication tool or just tweets and word games
    • And/but…  Pharma skeptical of social media
  • Huge. Watch what comes from this… RT @FierceBiotech: NIH steps in to propel research projects into the clinic.
  • Lilly Suspends Phase III Trial in Metastatic Melanoma (RT @PharmProEditor)
  • This may be a long road for DoD – I worked on a related project in ’91! RT @FierceBiotech: DoD awards $1.3M grant to develop artificial blood.
  • MaRS CEO Ilse Treurnicht notes that China is now 2nd in publication of biomedical research articles globally, recently surpassed Japan, UK, Germany…Canada…  Canadian expat Taylor Raborn asks: is their average publication of the same quality as those from Japan or Germany? Well, “quality” is hard to measure, of course. By citation rate, the answer is no. Nature has very cool data showing publication volume and citation rate
  • Venture Capital (VC) for Canada Campaign: B.C shows exemplary leadership, will others follow? RT @CVCACanada
  • 4-4 split leaves 9th Cir decision intact RT @patentlyo: Supreme Court Does not Decide Costco v. Omega Int’l Exhaustion Case

One response to “Weekend Reading: This Week in the Twitterverse

  1. Wayne Schnarr December 19, 2010 at 1:40 pm

    The words ‘artificial blood’, although a misleading description for what are really red blood cell substitutes, always attract my attention. The pathway to commercialize a hemoglobin-based product over the last two decades includes the demise of at least four public companies – Canada’s Hemosol, and the three U.S. companies Somatogen, Northfield and Biopure.

    This new program is probably most similar to Somatogen, which attempted the manufacturing of human hemoglobin using recombinant technologies. It is unlikely that people will line up to donate cerebrospinal fluid for the isolation of neuroglobin in the same way that they line up to donate blood (with or without financial compensation).

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


Get every new post delivered to your Inbox.

Join 128 other followers